Effects of a mushroom mycelium extract on the treatment of prostate cancer

Ralph W deVere White, Robert M. Hackman, Stephanie E. Soares, Laurel A Beckett, Buxiang Sun

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Objectives. To determine whether supplemental amounts of a polysaccharide/oligosaccharide complex obtained from a shiitake mushroom extract (SME) would lower the prostate-specific antigen (PSA) level in patients with prostate cancer. Methods. A total of 62 men (mean age 73.2 years, range 53.6 to 85.5) with histologically proven prostate cancer who had two consecutive elevated PSA readings were accrued to the study during a 3-month period. This was an open-label study in which the patients received oral administration of capsules containing SME given three times daily for 6 months. The endpoint for the trial was the lowering of the PSA levels. Results. Of the 62 men enrolled in the study, 61 were assessable. At 4 months, 1 patient withdrew because of unrelated surgery and 7 withdrew because of disease progression; none had responded with a decrease of greater than 50% in the PSA level. By 6 months, a total of 23 patients had progression and none had responded. Thirty-eight patients had stable PSA levels after 6 months. Although not the primary endpoint of the study, in other studies these patients could have been included as responders. When the patients' rates of PSA rise before study entry were analyzed, 4 (7%) had stabilized disease while taking SME. Thus, the final results for our study patients were 0 with a complete response, 0 with a partial response, 4 (7%) with stable disease, and 23 of 61 with progression while taking SME. Conclusions. SME alone is ineffective in the treatment of clinical prostate cancer.

Original languageEnglish (US)
Pages (from-to)640-644
Number of pages5
JournalUrology
Volume60
Issue number4
DOIs
StatePublished - Oct 1 2002

Fingerprint

Agaricales
Mycelium
Shiitake Mushrooms
Prostatic Neoplasms
Prostate-Specific Antigen
Therapeutics
Oligosaccharides
Capsules
Polysaccharides
Oral Administration
Disease Progression
Reading

ASJC Scopus subject areas

  • Urology

Cite this

Effects of a mushroom mycelium extract on the treatment of prostate cancer. / deVere White, Ralph W; Hackman, Robert M.; Soares, Stephanie E.; Beckett, Laurel A; Sun, Buxiang.

In: Urology, Vol. 60, No. 4, 01.10.2002, p. 640-644.

Research output: Contribution to journalArticle

deVere White, Ralph W ; Hackman, Robert M. ; Soares, Stephanie E. ; Beckett, Laurel A ; Sun, Buxiang. / Effects of a mushroom mycelium extract on the treatment of prostate cancer. In: Urology. 2002 ; Vol. 60, No. 4. pp. 640-644.
@article{56e428e136e545259db17799df2d8332,
title = "Effects of a mushroom mycelium extract on the treatment of prostate cancer",
abstract = "Objectives. To determine whether supplemental amounts of a polysaccharide/oligosaccharide complex obtained from a shiitake mushroom extract (SME) would lower the prostate-specific antigen (PSA) level in patients with prostate cancer. Methods. A total of 62 men (mean age 73.2 years, range 53.6 to 85.5) with histologically proven prostate cancer who had two consecutive elevated PSA readings were accrued to the study during a 3-month period. This was an open-label study in which the patients received oral administration of capsules containing SME given three times daily for 6 months. The endpoint for the trial was the lowering of the PSA levels. Results. Of the 62 men enrolled in the study, 61 were assessable. At 4 months, 1 patient withdrew because of unrelated surgery and 7 withdrew because of disease progression; none had responded with a decrease of greater than 50{\%} in the PSA level. By 6 months, a total of 23 patients had progression and none had responded. Thirty-eight patients had stable PSA levels after 6 months. Although not the primary endpoint of the study, in other studies these patients could have been included as responders. When the patients' rates of PSA rise before study entry were analyzed, 4 (7{\%}) had stabilized disease while taking SME. Thus, the final results for our study patients were 0 with a complete response, 0 with a partial response, 4 (7{\%}) with stable disease, and 23 of 61 with progression while taking SME. Conclusions. SME alone is ineffective in the treatment of clinical prostate cancer.",
author = "{deVere White}, {Ralph W} and Hackman, {Robert M.} and Soares, {Stephanie E.} and Beckett, {Laurel A} and Buxiang Sun",
year = "2002",
month = "10",
day = "1",
doi = "10.1016/S0090-4295(02)01856-3",
language = "English (US)",
volume = "60",
pages = "640--644",
journal = "Urology",
issn = "1527-9995",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Effects of a mushroom mycelium extract on the treatment of prostate cancer

AU - deVere White, Ralph W

AU - Hackman, Robert M.

AU - Soares, Stephanie E.

AU - Beckett, Laurel A

AU - Sun, Buxiang

PY - 2002/10/1

Y1 - 2002/10/1

N2 - Objectives. To determine whether supplemental amounts of a polysaccharide/oligosaccharide complex obtained from a shiitake mushroom extract (SME) would lower the prostate-specific antigen (PSA) level in patients with prostate cancer. Methods. A total of 62 men (mean age 73.2 years, range 53.6 to 85.5) with histologically proven prostate cancer who had two consecutive elevated PSA readings were accrued to the study during a 3-month period. This was an open-label study in which the patients received oral administration of capsules containing SME given three times daily for 6 months. The endpoint for the trial was the lowering of the PSA levels. Results. Of the 62 men enrolled in the study, 61 were assessable. At 4 months, 1 patient withdrew because of unrelated surgery and 7 withdrew because of disease progression; none had responded with a decrease of greater than 50% in the PSA level. By 6 months, a total of 23 patients had progression and none had responded. Thirty-eight patients had stable PSA levels after 6 months. Although not the primary endpoint of the study, in other studies these patients could have been included as responders. When the patients' rates of PSA rise before study entry were analyzed, 4 (7%) had stabilized disease while taking SME. Thus, the final results for our study patients were 0 with a complete response, 0 with a partial response, 4 (7%) with stable disease, and 23 of 61 with progression while taking SME. Conclusions. SME alone is ineffective in the treatment of clinical prostate cancer.

AB - Objectives. To determine whether supplemental amounts of a polysaccharide/oligosaccharide complex obtained from a shiitake mushroom extract (SME) would lower the prostate-specific antigen (PSA) level in patients with prostate cancer. Methods. A total of 62 men (mean age 73.2 years, range 53.6 to 85.5) with histologically proven prostate cancer who had two consecutive elevated PSA readings were accrued to the study during a 3-month period. This was an open-label study in which the patients received oral administration of capsules containing SME given three times daily for 6 months. The endpoint for the trial was the lowering of the PSA levels. Results. Of the 62 men enrolled in the study, 61 were assessable. At 4 months, 1 patient withdrew because of unrelated surgery and 7 withdrew because of disease progression; none had responded with a decrease of greater than 50% in the PSA level. By 6 months, a total of 23 patients had progression and none had responded. Thirty-eight patients had stable PSA levels after 6 months. Although not the primary endpoint of the study, in other studies these patients could have been included as responders. When the patients' rates of PSA rise before study entry were analyzed, 4 (7%) had stabilized disease while taking SME. Thus, the final results for our study patients were 0 with a complete response, 0 with a partial response, 4 (7%) with stable disease, and 23 of 61 with progression while taking SME. Conclusions. SME alone is ineffective in the treatment of clinical prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=0036775712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036775712&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(02)01856-3

DO - 10.1016/S0090-4295(02)01856-3

M3 - Article

C2 - 12385925

AN - SCOPUS:0036775712

VL - 60

SP - 640

EP - 644

JO - Urology

JF - Urology

SN - 1527-9995

IS - 4

ER -